<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple myeloma: Treatment of first or second relapse</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple myeloma: Treatment of first or second relapse</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple myeloma: Treatment of first or second relapse</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob P Laubach, MD, MPP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2673823476"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most patients with multiple myeloma (MM) will have an initial response to treatment. However, conventional therapy is not curative and MM will ultimately relapse. In addition, a minority will have primary refractory disease that does not respond to initial treatment.</p><p>The choice of therapy for MM in first or second relapse will be discussed here. Many of the same regimens can be used as later lines of therapy if not utilized previously. Administration considerations for common therapies, the initial treatment of MM, the treatment of third or later relapse, and the use of autologous and allogeneic hematopoietic cell transplantation are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H1714999770"><span class="h1">ASSESS DRUG SENSITIVITY</span><span class="headingEndMark"> — </span>The choice of therapy for relapsed MM must consider prior therapy, response, and likelihood of the disease being sensitive or refractory to prior agents  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). In general, refractory disease is defined as progressing on or within 60 days of receiving standard doses of a specific therapy.</p><p>As an example, MM progressing on or within 60 days of receiving standard doses of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> (eg, 25 mg daily) is refractory to lenalidomide, and such cases have been excluded from studies evaluating lenalidomide-containing regimens. In contrast, disease progression in a patient that previously received lenalidomide but not within the past 60 days or in a patient on a maintenance dose of single-agent lenalidomide (eg, 10 mg daily) is considered lenalidomide sensitive. Lenalidomide-sensitive MM may respond to a regimen that increases the dose of lenalidomide, reintroduces <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and/or adds a third agent (eg, a monoclonal antibody or a proteasome inhibitor). </p><p>Whether a patient is <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> sensitive or lenalidomide refractory represents an important determinant of second- or third-line therapy, since many of the regimens that have regulatory approval for this indication incorporate lenalidomide. Our approach is therefore structured according to disease status as it relates to sensitivity or refractoriness to lenalidomide  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1940173325"><span class="h1">LENALIDOMIDE SENSITIVE</span><span class="headingEndMark"> — </span>For most patients with lenalidomide-sensitive MM in first or second relapse, we suggest a lenalidomide-containing three-drug regimen  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). This includes patients who experience disease progression on a maintenance dose of single-agent <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> (eg, 10 mg daily). </p><p>This recommendation is based on evidence derived from phase 3 clinical trials described below evaluating regimens incorporating <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> in patients with relapsed MM who received one to three prior lines of therapy. While most of these trials excluded patients progressing on any dose of lenalidomide, we consider a lenalidomide-containing regimen as an option for patients progressing on a low dose of lenalidomide (≤10 mg). If a response to a lenalidomide-based regimen is not seen, a different regimen can then be pursued. This approach ensures that under appropriate clinical circumstances patients with lenalidomide-sensitive disease derive maximum benefit from lenalidomide and lenalidomide-based regimens before receiving other agents in subsequent lines of treatment.</p><p>We consider four-drug regimens for patients with highly aggressive disease. (See <a class="local">'Aggressive disease'</a> below.)</p><p class="headingAnchor" id="H518668770"><span class="h2">Daratumumab, lenalidomide, dexamethasone (DRd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DRd) is one of our preferred regimens for patients with lenalidomide-sensitive MM  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). DRd is approved in the United States, Europe, and many parts of Asia for patients with MM who have received at least one prior therapy. Details of the DRd regimen are provided in the table  (<a class="graphic graphic_table graphicRef119710" href="/z/d/graphic/119710.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">Although direct comparisons between DRd and other three-drug combinations have not been conducted, network meta-analyses that incorporated both direct and indirect comparisons identified DRd as among the most active regimens in relapsed MM among patients who had received one to three prior lines of therapy [<a href="#rid1">1-3</a>].</p><p></p><p class="bulletIndent1">As an example, a network meta-analysis that used single-agent <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> as a reference point identified DRd as the most effective three-drug regimen as illustrated by the hazard ratio (HR) for progression-free survival (PFS) [<a href="#rid2">2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>DRd (HR 0.13; 95% CI 0.09-0.19)</p><p class="bulletIndent2"><span class="glyph">•</span>KRd (HR 0.24; 95% CI 0.18-0.32)</p><p class="bulletIndent2"><span class="glyph">•</span>ERd (HR 0.25; 95% CI 0.19-0.33)</p><p class="bulletIndent2"><span class="glyph">•</span>DVd (HR 0.27; 95% CI 0.18-0.38)</p><p class="bulletIndent2"><span class="glyph">•</span>IRd (HR 0.26; 95% CI 0.19-0.35)</p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1">If available, we suggest the use of fixed-dose, subcutaneously administered <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a> in combination with <a class="drug drug_general" data-topicid="8657" href="/z/d/drug information/8657.html" rel="external">hyaluronidase</a> (<a class="drug drug_general" data-topicid="128088" href="/z/d/drug information/128088.html" rel="external">daratumumab-hyaluronidase</a>) rather than intravenous daratumumab. While most of the initial trials evaluating the efficacy of daratumumab used the intravenous formulation, the subcutaneous formulation has comparable efficacy with lower rates of infusion-related reactions, rapid administration time, similar drug cost, and lower total administration cost [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Anti-CD38 monoclonal antibodies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> alone (Rd), DRd improves PFS and overall survival (OS) without major increases in toxicity [<a href="#rid6">6-8</a>]. </p><p></p><p class="bulletIndent1">In a multicenter, open-label phase 3 trial (POLLUX), 569 patients with relapsed/refractory MM were randomly assigned to receive DRd versus Rd, each administered until disease progression or unacceptable toxicity [<a href="#rid6">6-8</a>]. The trial excluded MM progressing on any dose of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>. After a median follow-up of 80 months, DRd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher overall response rates (ORR; 93 versus 76 percent), very good partial response (VGPR) or better (78 versus 48 percent), and complete response (CR) or better (51 versus 21 percent) with higher rates of minimal residual disease negativity (33.2 versus 6.7 percent with a 10<sup>-5</sup> sensitivity threshold).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Superior PFS (83 versus 60 percent at 12 months; 68 versus 41 percent at 24 months; HR 0.41, 95% CI 0.31-0.53). On subgroup analysis, the PFS benefit did not differ by prior therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Superior OS (median OS 68 versus 52 months; HR 0.73; 95% CI 0.58-0.91). Prespecified subgroup analyses illustrated this OS benefit regardless of age, disease stage, and cytogenetic risk. The analysis also showed an OS benefit in patients with one prior line of therapy (median OS 78 versus 58 months). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with DRd on the POLLUX trial, approximately 12 percent discontinued therapy due to an adverse event [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1">When compared with Rd, DRd resulted in higher rates of neutropenia (59 versus 43 percent), diarrhea (43 versus 25 percent), upper respiratory tract infection (32 versus 21 percent), and cough (29 versus 13 percent). </p><p></p><p class="bulletIndent1">Other common nonhematologic toxicities of any grade were fatigue (35 percent), constipation (29 percent), and muscle spasms (26 percent). Infusion reactions (mostly mild) were reported in 48 percent of patients; of these, the vast majority (92 percent) occurred during the first infusion.  </p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were fatigue (6 percent) and diarrhea (5 percent).</p><p></p><p class="headingAnchor" id="H2523424457"><span class="h2">Carfilzomib, lenalidomide, dexamethasone (KRd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">Carfilzomib</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (KRd) is one of our preferred regimens for patients with lenalidomide-sensitive MM  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). KRd is approved in the United States and Europe for the treatment of relapsed MM. While carfilzomib results in less neurotoxicity than <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, there is a higher incidence of cardiac toxicity. We typically obtain pretreatment echocardiogram and electrocardiogram (EKG) to assess baseline cardiovascular status. Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with Rd alone, KRd improves PFS and OS without a major increase in toxicity. </p><p></p><p class="bulletIndent1">In a multicenter phase 3 trial (ASPIRE), 792 patients with relapsed MM were randomly assigned to receive KRd versus Rd [<a href="#rid9">9-12</a>]. Approximately 67 and 20 percent of patients had received prior <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, respectively. The trial excluded patients progressing on any dose of lenalidomide or bortezomib. When compared with Rd alone, KRd resulted in the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An improved ORR (87 versus 67 percent) along with deeper responses (CR 32 versus 9 percent, and stringent CR 14 versus 4 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median 26 versus 17 months; HR 0.66, 95% CI 0.55-0.78).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Superior OS (median 48 versus 40 months; HR 0.79, 95% CI 0.67-0.95).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved quality of life as measured by the QLQ-C30 Global Health Status and Quality of Life scale (difference 5.6 points).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with KRd on the ASPIRE trial, approximately 15 percent discontinued therapy due to an adverse event [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1">When compared with Rd, KRd resulted in higher rates of upper respiratory tract infections (30 versus 21 percent), hypokalemia (30 versus 15 percent), muscle spasms (27 versus 21 percent), and hypertension (17 versus 9 percent), but no increase in drug discontinuation due to toxicity.</p><p></p><p class="bulletIndent1">Other common nonhematologic toxicities of any grade were diarrhea (42 percent), fatigue (33 percent), cough (29 percent), pyrexia (29 percent), and hypokalemia (28 percent). </p><p></p><p class="bulletIndent1">Other adverse events of interest of any grade included dyspnea (19 percent), hypertension (14 percent), acute renal failure (8 percent), cardiac failure (6 percent), and ischemic heart disease (6 percent).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were hypokalemia (9 percent), fatigue (8 percent), and diarrhea (4 percent). </p><p></p><p class="headingAnchor" id="H218098315"><span class="h2">Ixazomib, lenalidomide, dexamethasone (IRd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">Ixazomib</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (IRd)  (<a class="graphic graphic_table graphicRef106536" href="/z/d/graphic/106536.html" rel="external">table 3</a>) is an all-oral alternative for patients with lenalidomide-sensitive MM  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). The combination is approved in the United States and Europe for the treatment of patients with MM who have received at least one prior therapy. We generally utilize this well tolerated regimen in patients with less aggressive disease and in situations where all-oral therapy is clearly preferred or necessary.</p><p></p><p class="bulletIndent1">Details of the IRd regimen are provided in the table  (<a class="graphic graphic_table graphicRef106536" href="/z/d/graphic/106536.html" rel="external">table 3</a>). Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with Rd alone, IRd improves PFS without a major increase in toxicity. </p><p></p><p class="bulletIndent1">In a multicenter phase 3 trial (Tourmaline-MM1), 722 adults with relapsed MM were randomly assigned to receive IRd versus Rd plus placebo [<a href="#rid13">13-16</a>]. To be included, patients had to have relapsed after one to three prior therapies and could not be refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> or proteasome inhibitor-based therapy. Therapy was continued until disease progression or unacceptable toxicity. At a median follow-up of 15 months, IRd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved ORR (78 versus 72 percent) and CR rate (12 versus 7 percent), PFS (median 21 versus 15 months; HR 0.74, 95% CI 0.59-0.94), and duration of response (21 versus 15 months). This benefit was seen in both high- and standard-risk cytogenetic subgroups. There was no clear difference in quality of life measures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Further follow-up after a median of 85 months showed similar OS despite the addition of <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">ixazomib</a> (median 54 versus 52 months; HR 0.94, 95% CI 0.78-1.13) [<a href="#rid16">16</a>]. At the time of progression, the group assigned to placebo were more likely to receive regimens that contained <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, and/or <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>. This difference in subsequent treatment confounds the interpretation of these data.</p><p></p><p class="bulletIndent1">A similar trial in previously untreated MM (TOURMALINE-MM2) demonstrated improved PFS but not OS with the addition of <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">ixazomib</a> to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with IRd on the Tourmaline-MM1 trial, approximately 17 percent discontinued therapy due to an adverse event [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">When compared with Rd, IRd resulted in a higher rate of grade 3 or 4 thrombocytopenia (19 versus 9 percent). Other common toxicities included diarrhea (45 percent), constipation (35 percent), nausea (29 percent), vomiting (23 percent), peripheral neuropathy (27 percent), peripheral edema (28 percent), and rash (36 percent). </p><p></p><p class="bulletIndent1">Other adverse events of interest of any grade included arrhythmias (16 percent); acute renal failure (9 percent); thromboembolism (8 percent); liver impairment (7 percent); hypertension (6 percent); hypotension (6 percent); heart failure (4 percent); and myocardial infarction, encephalopathy, and interstitial lung disease (≤1 percent each).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were diarrhea (6 percent), rash (5 percent), and fatigue (4 percent). </p><p></p><p class="headingAnchor" id="H97375427"><span class="h2">Elotuzumab, lenalidomide, dexamethasone (ERd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">Elotuzumab</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (ERd) is approved in the United States, Europe, and many parts of Asia for patients with MM who have received at least one prior therapy  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). We typically utilize ERd in patients with less aggressive disease characteristics. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– When compared with Rd alone, ERd improves PFS and OS without a major increase in toxicity in relapsed or refractory MM. </p><p></p><p class="bulletIndent1">In an open-label, multicenter, phase 3 trial (ELOQUENT-2), 646 patients with MM relapsed after one to three prior lines of therapy were randomly assigned to receive ERd versus Rd [<a href="#rid18">18-20</a>]. The trial excluded patients progressing on any dose of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>. All patients received thromboembolic prophylaxis and those assigned to <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">elotuzumab</a> received premedication with <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, <a class="drug drug_general" data-topicid="9853" href="/z/d/drug information/9853.html" rel="external">ranitidine</a>, and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, or their equivalents. After a median follow-up of 46 months, ERd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median 19 versus 15 months; one-year PFS 68 versus 57 percent; four-year PFS 21 versus 14 percent; HR 0.71, 95% CI 0.59-0.86). Subgroup analysis demonstrated similar efficacy across age groups and disease risk groups, including those with del(17p).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved OS (median 48 versus 40 months; four-year OS 50 versus 43 percent; HR 0.78, 95% CI 0.63-0.96).</p><p></p><p class="bulletIndent1">In contrast, another randomized trial of ERd versus Rd in newly diagnosed, transplant ineligible MM (ELOQUENT-1) did not demonstrate a PFS benefit with the addition of <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">elotuzumab</a> (HR 0.93, 95% CI 0.77-1.12) [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with ERd on the ELOQUENT-2 trial, approximately 9 percent discontinued therapy due to an adverse event [<a href="#rid18">18</a>]. When compared with Rd, ERd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A higher rate of severe (grade 3 or 4) adverse events (78 versus 67 percent). There was an increased incidence of opportunistic infection (22 versus 13 percent), including fungal infection (10 versus 5 percent) and herpes zoster infection (14 versus 7 percent) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A higher rate of invasive second primary malignancies (9 versus 6 percent), including solid tumors (3.5 versus 2.2 percent) and skin cancer (4.4 versus 2.8 percent) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">Infusion reactions occurred in 10 percent of patients. The majority (70 percent) occurred with the first infusion and only two patients discontinued treatment due to an infusion reaction.</p><p></p><p class="bulletIndent1">Other common nonhematologic toxicities of any grade were diarrhea (47 percent), fatigue (47 percent), pyrexia (37 percent), constipation (36 percent), cough (31 percent), muscle spasms (30 percent), back pain (28 percent), peripheral edema (26 percent), nasopharyngitis (25 percent), and insomnia (23 percent).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were fatigue (8 percent), diarrhea (5 percent), back pain (5 percent), and pyrexia (3 percent).</p><p></p><p class="headingAnchor" id="H82970625"><span class="h1">LENALIDOMIDE REFRACTORY</span><span class="headingEndMark"> — </span>For patients with lenalidomide-refractory MM, the choice among non-lenalidomide-containing regimens is influenced by whether the disease is refractory to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and/or <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). </p><p>MM refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> may respond to a combination that incorporates a different proteasome inhibitor (eg, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>) or a different immunomodulatory agent (eg, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>), in combination with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and a monoclonal antibody (eg, <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>). In contrast, MM refractory to both lenalidomide and daratumumab is presumed to be resistant to other anti-CD38 monoclonal antibodies and is typically treated with non-antibody-containing regimens.</p><p class="headingAnchor" id="H1141616577"><span class="h2">Refractory to lenalidomide alone</span><span class="headingEndMark"> — </span>For patients with MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> alone, we offer <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DVd); daratumumab, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and dexamethasone (DPd); <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">isatuximab</a>, pomalidomide, and dexamethasone (IsaPd); or bortezomib, pomalidomide, and dexamethasone (VPd)  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H3402077793"><span class="h3">Daratumumab, bortezomib, dexamethasone (DVd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DVd) is one of our preferred regimens for patients with relapsed MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). DVd is approved in the United States, Europe, and many parts of Asia for patients with MM who have received at least one prior therapy. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1">Although direct comparisons between DVd and other three-drug combinations have not been conducted, two network meta-analyses that incorporated both direct and indirect comparisons identified monoclonal antibody-containing three-drug combinations such as DVd as the most active regimens in relapsed MM [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1">If available, we suggest the use of fixed-dose, subcutaneously administered <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a> in combination with <a class="drug drug_general" data-topicid="8657" href="/z/d/drug information/8657.html" rel="external">hyaluronidase</a> (<a class="drug drug_general" data-topicid="128088" href="/z/d/drug information/128088.html" rel="external">daratumumab-hyaluronidase</a>) rather than intravenous daratumumab. While most of the initial trials evaluating the efficacy of daratumumab used the intravenous formulation, the subcutaneous formulation appears to have similar efficacy with lower rates of infusion-related reactions, a faster administration time, similar drug cost, and lower total administration cost [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Anti-CD38 monoclonal antibodies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> alone (Vd), DVd improves progression-free survival (PFS) and overall survival (OS) without major increases in toxicity. </p><p></p><p class="bulletIndent1">In a multicenter, open-label phase 3 trial (CASTOR), 498 patients with relapsed/refractory MM were randomly assigned to receive up to eight cycles of DVd versus Vd [<a href="#rid23">23-26</a>]. The trial excluded patients refractory to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> or another proteasome inhibitor. After a prespecified interim analysis at a median follow-up of 7.4 months found that DVd was associated with improved PFS, the trial was stopped early and patients assigned to Vd were offered <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a> at the time of progression. After a median follow-up of 73 months, DVd was associated with the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher overall response rate (ORR; 84 versus 63 percent), very good partial response (VGPR) or better (62 versus 29 percent), and complete response (CR) or better (29 versus 10 percent) with higher rates of minimal residual disease negativity (15.1 versus 1.6 percent with a 10<sup>-5</sup> sensitivity threshold). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median 16.7 versus 7.1 months; HR 0.31, 95% CI 0.25-0.40). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved OS (median 49.6 versus 38.5 months; HR 0.74, 95% CI 0.59-0.92). Prespecified subgroup analyses illustrated this OS benefit regardless of age, disease stage, and cytogenetic risk.  </p><p></p><p class="bulletIndent1">Another randomized phase 3 trial (LEPUS) of DVd versus Vd in 211 Chinese patients reported a similar PFS benefit (HR 0.28, 95% CI 0.17-0.47) and safety profile [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with DVd on the CASTOR trial, approximately 7 percent discontinued therapy due to an adverse event [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent1">When compared with Vd, DVd resulted in higher rates of thrombocytopenia (60 versus 44 percent), neutropenia (20 versus 10 percent), lymphopenia (13 versus 4 percent), peripheral sensory neuropathy (50 versus 38 percent), and second primary cancers (4.1 versus 0.4 percent).</p><p></p><p class="bulletIndent1">Infusion reactions (mostly mild) were reported in 45 percent of patients; of these, the vast majority (98 percent) occurred during the first infusion.</p><p></p><p class="bulletIndent1">Other common nonhematologic toxicities of any grade were diarrhea (32 percent), upper respiratory tract infection (25 percent), fatigue (21 percent), cough (24 percent), constipation (20 percent), dyspnea (19 percent), insomnia (17 percent), and peripheral edema (17 percent).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were pneumonia (8 percent), hypertension (7 percent), peripheral sensory neuropathy (5 percent), fatigue (5 percent), diarrhea (4 percent), and dyspnea (4 percent).</p><p></p><p class="headingAnchor" id="H2649543613"><span class="h3">Bortezomib, pomalidomide, dexamethasone (VPd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VPd) is an off-label combination for the treatment of MM. We consider it to be an acceptable alternative for patients refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> alone or to lenalidomide and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with Vd alone, VPd improves PFS. </p><p></p><p class="bulletIndent1">In an international phase 3 trial (OPTIMISMM), 559 patients with MM progressing after prior <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> were randomly assigned to receive VPd versus Vd [<a href="#rid28">28-30</a>]. Approximately 75 percent had received a prior proteasome inhibitor and 70 percent were refractory to lenalidomide. After a median follow-up of 16 months, VPd resulted in the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An improved ORR (82 versus 50 percent) with deeper responses (CR 12 versus 3 percent, and stringent CR 3 versus &lt;1 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median 11 versus 7 months; HR 0.61, 95% CI 0.49-0.77). A PFS benefit was seen in high- and standard-risk MM, MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and MM with prior <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> exposure. OS data are not mature.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar scores on assessment of health-related quality of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In the patients treated with VPd on the OPTIMISMM trial, adverse events resulted in treatment discontinuation in 11 percent [<a href="#rid28">28</a>]. There were six deaths attributed to toxicity (pneumonia, cardiac arrest, and unknown cause). When compared with Vd, VPd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of neutropenia (42 versus 9 percent), infection (31 versus 18 percent), and febrile neutropenia (3 percent versus none). Use of antiviral, antibiotic, and antifungal agents were at the discretion of the investigator.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>More grade 3 or 4 thromboembolic events (13 versus 2 cases, none fatal) despite mandatory prophylactic antithrombotic therapy for those assigned to VPd. </p><p></p><p class="bulletIndent1">Other common toxicities of any grade were peripheral neuropathy (48 percent), constipation (37 percent), peripheral edema (37 percent), fatigue (37 percent), diarrhea (34 percent), pyrexia (23 percent), cough (21 percent), upper respiratory tract infection (21 percent), and back pain (19 percent). </p><p></p><p class="bulletIndent1">The most common grade 3 or 4 toxicities were pneumonia (11 percent), hyperglycemia (9 percent), peripheral neuropathy (8 percent), fatigue (8 percent), and diarrhea (7 percent).</p><p></p><p class="headingAnchor" id="H255641000"><span class="h2">Refractory to lenalidomide and bortezomib</span><span class="headingEndMark"> — </span>Patients who have experienced disease progression on or within 60 days of receiving standard doses of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> are considered to be refractory to both agents. Such patients may respond to a combination that incorporates a different proteasome inhibitor (eg, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>) or a different immunomodulatory agent (eg, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>), in combination with a monoclonal antibody (eg, <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>). </p><p>For patients with MM refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, we offer either <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DKd) or <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">isatuximab</a>, carfilzomib, and dexamethasone (IsaKd)  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). Other options in this context are daratumumab, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and dexamethasone (DPd); isatuximab, pomalidomide, and dexamethasone; and <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">elotuzumab</a>, pomalidomide, and dexamethasone (EPd).</p><p class="headingAnchor" id="H1130902409"><span class="h3">Daratumumab, carfilzomib, dexamethasone (DKd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DKd) is one of our preferred treatments for patients with relapsed MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). DKd is approved in the United States for patients with MM who have received one to three prior lines of therapy. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> alone (Kd), DKd improves PFS without major increases in toxicity. [<a href="#rid1">1,2</a>]. </p><p></p><p class="bulletIndent1">In a multicenter, open-label phase 3 trial (CANDOR), 466 patients with relapsed/refractory MM were randomly assigned 2:1 to receive DKd versus Kd, each administered until disease progression or unacceptable toxicity [<a href="#rid31">31,32</a>]. After a median follow-up of 28 months, DKd improved ORR (84 versus 73 percent) and PFS (median 28.6 versus 15.2 months; HR 0.59, 95% CI 0.46-0.78). OS data are not yet mature.</p><p></p><p class="bulletIndent1">When compared with the general MM population, enrolled patients were younger (median age 64 years) and more fit (95 percent with Eastern Cooperative Oncology Group performance status [ECOG PS] 0 or 1). Older patients and those with intermediate fitness had higher rates of treatment-related fatal adverse events with DKd.</p><p></p><p class="bulletIndent1">While twice-weekly <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a> was used in the CANDOR trial described below, DKd can be given using once-weekly carfilzomib (20/70 mg/m<sup>2</sup>). Support for this alternative dosing comes from a nonrandomized phase 1b study (EQUULEUS, NCT01998971) that used DKd with once-weekly carfilzomib in 85 patients with relapsed or refractory MM [<a href="#rid33">33</a>]. A cross-trial comparison versus CANDOR suggested comparable efficacy and safety to twice-weekly dosing with an ORR of 81 percent and an estimated median duration of response of 28 months [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity </strong>– In patients treated with DKd on the CANDOR trial, approximately 26 percent discontinued therapy due to an adverse event [<a href="#rid31">31,32</a>]. Fatal adverse events occurred in 9 percent, including respiratory tract infections and cardiac failure. </p><p></p><p class="bulletIndent1">When compared with Kd, DKd resulted in more treatment-emergent fatal adverse events (9 versus 5 percent), more grade 3 or greater adverse events (87 versus 76 percent), and higher all grade rates of diarrhea (36 versus 17 percent), upper respiratory tract infection (33 versus 23 percent), and fatigue (25 versus 19 percent).</p><p></p><p class="bulletIndent1">Other common nonhematologic toxicities of any grade were hypertension (35 percent), dyspnea (23 percent), and pneumonia (24 percent).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were hypertension (21 percent), pneumonia (17 percent), fatigue (8 percent), dyspnea (5 percent), diarrhea (5 percent), and upper respiratory tract infection (4 percent).</p><p></p><p class="bulletIndent1">Other adverse events of interest of any grade included respiratory tract infections (78 percent), viral infections (24 percent), peripheral neuropathy (20 percent), infusion reaction (45 percent), cardiac failure (9 percent), and acute renal failure (7 percent).</p><p></p><p class="headingAnchor" id="H1605225651"><span class="h3">Isatuximab, carfilzomib, dexamethasone (IsaKd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">Isatuximab</a>, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (IsaKd) is one of our preferred treatments for patients with relapsed MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). IsaKd is approved in the United States for patients with relapsed or refractory MM who have received one to three prior lines of therapy. IsaKd is approved in Europe for patients who have received at least one prior therapy. IsaKd is approved in parts of Asia for certain adults with relapsed MM. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with Kd alone, IsaKd improves PFS without major increases in toxicity. </p><p></p><p class="bulletIndent1">In an open-label, multicenter, phase 3 trial (IKEMA), 302 patients with relapsed MM who had received one to three prior lines of therapy were randomly assigned in a 3:2 ratio to receive IsaKd versus Kd until disease progression or unacceptable toxicity [<a href="#rid35">35,36</a>]. After a median follow-up of 21 months, IsaKd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A similar ORR (87 versus 83 percent), with deeper responses (VGPR or better 73 versus 56 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median not reached versus 19 months, HR 0.53, 95% CI 0.32-0.89). OS data are immature.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with IsaKd on the IKEMA trial, adverse reactions resulted in dose interruptions in 33 percent and treatment discontinuation in 8 percent [<a href="#rid36">36</a>]. Fatal adverse reactions occurred in 3 percent, including pneumonia and cardiac failure.</p><p></p><p class="bulletIndent1">The most common adverse reactions of any grade were infusion-related reactions (46 percent), fatigue (28 percent), hypertension (37 percent), diarrhea (36 percent), upper respiratory tract infection (36 percent), pneumonia (29 percent), dyspnea (28 percent), and bronchitis (23 percent). Over 90 percent of patients developed anemia and thrombocytopenia. Neutropenia developed in 55 percent and was grade 3 or greater in 19 percent.</p><p></p><p class="bulletIndent1">The most common grade 3 or greater nonhematologic toxicities were pneumonia (21 percent) and hypertension (20 percent). </p><p></p><p class="headingAnchor" id="H2331248275"><span class="h3">Daratumumab, pomalidomide, dexamethasone (DPd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DPd) is a widely used regimen for patients with MM refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). DPd is approved in the United States for patients with MM who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In a multicenter, open-label phase 3 trial (APOLLO), 304 patients with relapsed/refractory MM were randomly assigned to receive <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (Pd) with or without subcutaneous <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, each administered until disease progression or unacceptable toxicity [<a href="#rid37">37</a>]. The addition of daratumumab improved PFS (median PFS 12.4 versus 6.9 months, HR 0.63, 95% CI 0.47-0.85). OS data are immature.  </p><p></p><p class="bulletIndent1">These results were consistent with those seen in two open-label, nonrandomized trials of DPd, which reported estimated one-year PFS of 66 and 75 percent among patients who had received at least two (MMY1001) or one to two (MM-014) prior regimens, respectively [<a href="#rid38">38,39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with DPd on the APOLLO trial, approximately 2 percent discontinued therapy due to an adverse event [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1">When compared with Pd, DPd resulted in more neutropenia (71 versus 54 percent), febrile neutropenia (9 versus 4 percent), and infections (65 versus 52 percent).</p><p></p><p class="bulletIndent1">Other common nonhematologic toxicities of any grade were pyrexia (20 percent); fatigue, asthenia, and diarrhea (17 percent each); hyperglycemia (5 percent); and infusion-related reaction (5 percent, all grade 1 or 2).   </p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were infections (24 percent), fatigue (8 percent), asthenia (6 percent), hyperglycemia (6 percent), and diarrhea (5 percent).   </p><p></p><p class="headingAnchor" id="H3050405179"><span class="h3">Isatuximab, pomalidomide, dexamethasone (IsaPd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">Isatuximab</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (IsaPd) is an acceptable alternative in patients with relapsed MM refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). IsaPd is approved in the United States, Europe, and Asia for patients with MM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– When compared with Pd, IsaPd improves PFS without major increases in toxicity. </p><p></p><p class="bulletIndent1">In an open-label, multicenter, phase 3 trial (ICARIA-MM), 307 patients with MM who had received at least two lines of prior therapy, including <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and a proteasome inhibitor, were randomly assigned to receive IsaPd versus Pd [<a href="#rid40">40,41</a>]. After a median follow-up of 35 months, IsaPd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A higher ORR (63 versus 33 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median 11 versus 6 months; HR 0.6, 95% CI 0.46-0.78).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An estimated 7 month improvement in median OS (median 25 versus 18 months; HR 0.76; 95% CI 0.57-1.01). While not statistically significant at current follow-up, this OS benefit would be clinically meaningful if confirmed with longer follow-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a prespecified subgroup analysis, the addition of <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">isatuximab</a> improved ORR and PFS in patients with high-risk MM [<a href="#rid42">42</a>], and in patients with renal impairment [<a href="#rid43">43</a>]. Pharmacokinetic studies suggested no need for isatuximab dose adjustment for renal insufficiency. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with IsaPd on the ICARIA-MM trial, approximately 12 percent discontinued therapy due to an adverse event [<a href="#rid40">40,41</a>]. When compared with Pd, IsaPd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A higher rate of grade 3 or greater adverse events (91 versus 75 percent), and a similar number of fatal adverse events (14 versus 15 patients).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of upper respiratory tract infections (33 versus 19 percent), diarrhea (30 versus 22 percent), and second primary malignancies (7 versus 2 percent). </p><p></p><p class="bulletIndent1">Other common nonhematologic toxicities of any grade were infusion reactions (38 percent, mostly mild), bronchitis (24 percent), pneumonia (23 percent), fatigue (18 percent), back pain (16 percent), constipation (16 percent), asthenia (14 percent), dyspnea (15 percent), and nausea (15 percent).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were pneumonia (23 percent), lower respiratory tract infection (5 percent), and urinary tract infection (5 percent).</p><p></p><p class="headingAnchor" id="H2020652268"><span class="h3">Elotuzumab, pomalidomide, dexamethasone (EPd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">Elotuzumab</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (EPd) is approved in the United States and Europe for MM following at least two prior lines of therapy, including <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and a proteasome inhibitor  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). EPd is approved in parts of Asia for certain adults with relapsed MM. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with Pd, EPd improves PFS and OS without a major increase in toxicity.  </p><p></p><p class="bulletIndent1">In an open-label, multicenter, phase 2 trial (ELOQUENT-3), 117 patients with MM refractory to or relapsed and refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and a proteasome inhibitor were randomly assigned to receive EPd versus Pd [<a href="#rid44">44,45</a>]. After a minimum follow-up of 45 months, EPd resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A higher ORR (53 versus 26 percent) with a median time to response of two months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median 10.3 versus 4.7 months; HR 0.54, 95% CI 0.34-0.86).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved OS (median 30 versus 17 months; HR 0.59; 95% CI 0.37-0.93).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity </strong>– In the patients treated with EPd on the ELOQUENT-3 trial, adverse events resulted in treatment discontinuation in 18 percent [<a href="#rid44">44,45</a>]. There were no deaths attributed to toxicity. When compared with Pd, EPd resulted in similar rates of grade 3 or 4 adverse events (60 versus 62 percent) and adverse events leading to treatment discontinuation (18 versus 24 percent). Infection rates were similar between the treatment groups (70 versus 66 percent). Second primary malignancies developed in four patients assigned to EPd and two patients assigned to Pd. </p><p></p><p class="bulletIndent1">The most common nonhematologic toxicities of any grade were nasopharyngitis (25 percent), diarrhea (25 percent), constipation (23 percent); hyperglycemia (22 percent); pyrexia and respiratory tract infection (20 percent each); fatigue, edema, and bone pain (18 percent each); insomnia and bronchitis (17 percent); muscle spasms (15 percent each); asthenia (13 percent); hypokalemia (12 percent); and rash, cataract, and pneumonia (10 percent each). </p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were hyperglycemia and cataract (8 percent each).</p><p></p><p class="headingAnchor" id="H2850978275"><span class="h2">Refractory to lenalidomide and daratumumab</span><span class="headingEndMark"> — </span>For patients with MM refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, we offer the combination <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (KPd); <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, pomalidomide, and dexamethasone (VPd); bortezomib, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and dexamethasone (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 4</a>); or <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">selinexor</a>, bortezomib, and dexamethasone (SVd)  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>).</p><p>Patients who experience disease progression on or within 60 days of receiving standard doses of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a> are considered to be refractory to both agents. Of note, a patient who progresses on once-monthly daratumumab may respond to daratumumab when the agent is administered once weekly.  </p><p>We have limited data addressing whether MM that is refractory to one anti-CD38 monoclonal antibody will respond to another. Although preliminary reports of some trials have described responses to isatuximab-based combinations following <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, in one small phase 2 study, no patients with MM refractory to daratumumab responded to single-agent <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">isatuximab</a> [<a href="#rid46">46</a>]. As such, we presume that MM refractory to one anti-CD38 monoclonal antibody is refractory to other anti-CD38 monoclonal antibodies. </p><p class="headingAnchor" id="H3955725954"><span class="h3">Carfilzomib, pomalidomide, dexamethasone (KPd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use </strong>– <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">Carfilzomib</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (KPd) is a preferred treatment for patients with relapsed MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, regardless of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> sensitivity  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). This includes patients progressing on or within 60 days of daratumumab, lenalidomide, and dexamethasone (DRd). </p><p></p><p class="bulletIndent1">KPd is an off-label combination for the treatment of MM. Phase 1/2 studies have used once-weekly [<a href="#rid47">47</a>] or twice-weekly [<a href="#rid48">48</a>] dosing of <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>. We typically prefer once-weekly dosing. Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – KPd has been evaluated in phase 1/2 multicenter dose escalation trials that enrolled patients refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid47">47-49</a>]. In these trials, responses were seen in approximately 50 to 60 percent of patients on the maximum tolerated dose (MTD), and responses were similar regardless of whether or not the patient was refractory to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>. While no randomized trials have evaluated KPd, randomized trials have demonstrated a clinical benefit from the use of <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a> and <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a> in other combinations used to treat relapsed MM (eg, KRd versus Rd, VPd versus Vd) [<a href="#rid9">9-12,28-30</a>]. </p><p></p><p class="bulletIndent1">A multicenter phase 1/2 study (NCT02185820) evaluated once-weekly KPd in 57 patients who had received one to three prior therapies and were refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid47">47</a>]. Responses were observed in 29 of 47 patients (62 percent) who received the MTD of <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a> (27 mg/m<sup>2</sup>), with a median time to partial response of two months. After a median follow-up of 13 months, the median PFS was 10.3 months and did not differ by <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> sensitivity. Median OS was not reached, and OS at one year was 67 percent.</p><p></p><p class="bulletIndent1">Another multicenter phase 1/2 study (NCT01464034) evaluated twice-weekly KPd in 32 patients refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid48">48</a>]. Patients had received a median of six prior therapies and 91 percent were refractory to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>. The ORR was 50 percent (16 percent VGPR, 34 percent PR). After a median follow-up of 26 months, median PFS was 7.2 months (95% CI 3-9 months) and median OS was 21 months.   </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – The most common adverse events described in the two phase 1/2 studies were as follows:</p><p></p><p class="bulletIndent1">With once-weekly KPd (NCT02185820): Most common nonhematologic adverse events of any grade included infection (43 percent); fever (34 percent); neuropathy and fatigue (23 percent each); hypertension, dermatologic, gastrointestinal (15 percent each); cardiac (6 percent); and renal failure (4 percent) [<a href="#rid47">47</a>]. Most common grade 3 or 4 nonhematologic adverse events were infections (11 percent), vascular events (9 percent), cardiac events (4 percent), and fatigue (4 percent). There were no treatment-related deaths.  </p><p></p><p class="bulletIndent1">With twice-weekly KPd (NCT01464034): Most common nonhematologic adverse events of any grade included fatigue (47 percent); creatinine elevation (38 percent); constipation, neuropathy, and muscle spasm (19 percent each); and diarrhea, rash, and hypocalcemia (16 percent each) [<a href="#rid48">48</a>]. Grade 3 or greater adverse events included one patient each with congestive heart failure, fluid overload, muscle weakness, maculopapular rash, and dyspnea, and three patients with acute renal failure. There were two treatment-related deaths (pulmonary embolism and pneumonia).   </p><p></p><p class="headingAnchor" id="H3711513187"><span class="h3">Bortezomib, cyclophosphamide, dexamethasone (VCd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 4</a>), also called CyBorD) is an important treatment option for patients with relapsed MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). Both bortezomib and cyclophosphamide are approved in the United States and Europe for the treatment of MM. Details of the VCd regimen are provided in the table  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 4</a>). </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Three randomized trials compared VCd versus other regimens in patients with previously untreated MM. A randomized phase 2 trial (EVOLUTION) evaluating <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> in combination with <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> (VRd), <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (VCd), or both (VDCR) reported ORR rates of 73, 68, and 80 percent, respectively [<a href="#rid50">50</a>]. In an open-label phase 3 trial that enrolled 155 patients in first relapse, VCd and lenalidomide, cyclophosphamide, and dexamethasone (RCd) resulted in similar PFS (median 16 versus 19 months) and OS (48 versus 51 percent at three years), but a different toxicity profile (VCd resulted in less neutropenia and thrombocytopenia, but more infections) [<a href="#rid51">51</a>]. In a multicenter phase 3 trial (IFM2013-04) comparing VCD versus bortezomib, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and dexamethasone (VTD), VCD resulted in a lower ORR (83 versus 92 percent) and more hematologic toxicity but less neurologic toxicity [<a href="#rid52">52</a>]. There were five deaths during induction, three in the VCD arm (infections and disease progression) and two in the VTD arm (infection, pulmonary embolism). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.) </p><p></p><p class="bulletIndent1">A phase 2 trial evaluated a different regimen of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and continuous low-dose <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> in 50 patients with relapsed MM yielded ORRs and CR rates of 66 and 16 percent, respectively [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with VCd in the EVOLUTION trial, adverse events resulted in treatment discontinuation in 12 percent [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1">Grade 3 or 4 hematologic toxicities included neutropenia (30 percent), lymphopenia (12 percent), and thrombocytopenia (12 percent).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities were neuropathy (9 percent), fatigue (3 percent), and diarrhea (3 percent).</p><p></p><p class="headingAnchor" id="H3660020743"><span class="h3">Selinexor, bortezomib, dexamethasone (SVd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">Selinexor</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> is another option for patients with MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>). It is approved in the United States for MM following at least one prior therapy [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent1">Specific administration considerations are discussed separately  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The combination of once-weekly SVd was compared with twice-weekly <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (Vd) in a multicenter, open label, phase 3 trial (BOSTON) of 402 patients with relapsed or refractory MM (median age 67 years, 48 percent with high-risk cytogenetics, 76 percent with prior proteasome inhibitor exposure) [<a href="#rid55">55,56</a>]. Both arms used subcutaneous bortezomib. Planned total doses of bortezomib and dexamethasone were lower in the SVd arm. Once-weekly SVd resulted in a higher ORR (76 versus 62 percent), and prolonged PFS (median 14 versus 9.5 months; HR 0.70). Crossover was allowed at progression and OS data are immature.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – In patients treated with SVd in the BOSTON trial, adverse events lead to treatment discontinuation in 21 percent and there were 12 deaths (6 percent) due to adverse events (leading causes pneumonia and sepsis). </p><p></p><p class="bulletIndent1">When compared with twice-weekly Vd, weekly SVd resulted in less peripheral neuropathy (32 versus 47 percent), and more cytopenias, infections, gastrointestinal toxicity, fatigue, and cataracts.</p><p></p><p class="bulletIndent1">SVd resulted in higher rates of grade 3 or 4 thrombocytopenia (39 versus 17 percent), anemia (16 versus 10 percent), and neutropenia (9 versus 3 percent).</p><p></p><p class="bulletIndent1">The most common grade 3 or 4 nonhematologic toxicities with SVd were fatigue (13 percent), pneumonia (12 percent), and cataracts (9 percent).</p><p></p><p class="headingAnchor" id="H3000756113"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1036325020"><span class="h2">Frail patients</span><span class="headingEndMark"> — </span>When possible, we prefer three-drug regimens over two-drug regimens. Indeed, many older adults were included in the trials that evaluated three-drug regimens and demonstrated superiority over two-drug regimens. However, two-drug regimens are an acceptable alternative for frail patients who are unable to tolerate three-drug regimens.</p><p>Single-agent therapy is used occasionally in frail patients who are unable to tolerate steroids, or in patients who have been well controlled on three-drug or two-drug regimens with a goal of reducing the intensity of therapy in order to minimize side effects. </p><p>Two-drug regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ixazomib</strong><strong> plus </strong><strong>dexamethasone</strong><strong> (Id)</strong> – In a phase 2 trial of <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">ixazomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> in 70 patients with relapsed MM not refractory to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, approximately 43 percent achieved a partial response (PR) or better [<a href="#rid57">57</a>]. The median event-free survival (EFS) was 8.4 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carfilzomib</strong><strong> plus </strong><strong>dexamethasone</strong><strong> (Kd)</strong> – In a multicenter, phase 3 trial (ENDEAVOR) comparing <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> versus <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> plus dexamethasone in patients with MM relapsed after one to three prior therapies, Kd improved overall response rate (ORR; 77 versus 63 percent), progression-free survival (PFS; median 19 versus 9 months; HR 0.53, 95% CI 0.44-0.65) and overall survival (OS; median 48 versus 39 months; HR 0.76, 95% CI 0.63-0.92) [<a href="#rid58">58-62</a>]. </p><p></p><p class="bulletIndent1">Kd also resulted in fewer dose reductions due to an adverse event (23 versus 48 percent); lower rates of all-grade peripheral neuropathy (19 versus 52 percent) and constipation (15 versus 27 percent); higher rates of dyspnea (29 versus 13 percent), pyrexia (28 versus 14 percent), cough (25 versus 14 percent), hypertension (25 versus 9 percent), and cardiac failure (8 versus 3 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bortezomib</strong><strong> plus </strong><strong>dexamethasone</strong><strong> (Vd)</strong> – In one study of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, the response rate was 66 percent in relapsed disease with a median time to progression of 9.5 months [<a href="#rid63">63</a>]. Similar ORRs are seen in patients with an initial PR or better with bortezomib therapy who undergo repeat treatment with bortezomib at progression [<a href="#rid64">64,65</a>]. </p><p></p><p class="bulletIndent1">Common adverse effects with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> include anorexia, nausea and vomiting, peripheral neuropathy, cutaneous reactions, neutropenia, and thrombocytopenia [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1">Kd was superior to Vd in the ENDEAVOR study as noted above, but Vd may be preferred to Kd in a frail, elderly patient with a history of significant cardiovascular disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pomalidomide</strong><strong> plus </strong><strong>dexamethasone</strong><strong> (Pd)</strong> – <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">Pomalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> results in a response rate of approximately 60 percent in relapsed disease [<a href="#rid68">68</a>], and approximately 30 percent in patients with lenalidomide-refractory disease [<a href="#rid69">69-73</a>]. Randomized trials have shown improved survival with Pd when compared with high-dose dexamethasone alone and higher response rates when compared with pomalidomide alone [<a href="#rid71">71,74</a>]. The duration of response ranged from 4 to 10 months in these multiply relapsed patients.</p><p></p><p class="bulletIndent1">Data regarding safety also come from a phase 3b study of Pd in patients with multiply relapsed or refractory MM [<a href="#rid75">75</a>]. <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">Pomalidomide</a> dose interruption, dose reduction, and discontinuation were observed in 66, 22, and 6 percent of patients, respectively. There were 15 deaths due to toxicity (2 percent). The most common severe (grade 3/4/5) toxicities were neutropenia (50 percent with 5.3 percent neutropenic fever), anemia (33 percent), infections (30 percent, including pneumonia in 13 percent), and thrombocytopenia (24 percent). </p><p></p><p class="bulletIndent1">Patients with moderate to severe renal impairment were excluded from these randomized trials; however, a small phase 2 trial of Pd suggested that this regimen is safe and effective in patients with moderate to severe renal insufficiency, including in those requiring dialysis [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenalidomide</strong><strong> plus </strong><strong>dexamethasone</strong><strong> (Rd)</strong> – In two large randomized phase 3 studies (MM-009 and MM-010) that compared <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> versus dexamethasone plus placebo in relapsed or refractory MM, Rd improved response rates and time to progression [<a href="#rid77">77-79</a>]. </p><p></p><p class="bulletIndent1">The most common severe (grade 3/4) toxicities seen in patients treated with Rd include neutropenia (30 to 40 percent), anemia (9 to 13 percent), thrombocytopenia (12 to 15 percent), and venous thromboembolism (11 percent). Nonhematologic toxicities of fatigue (55 percent), insomnia (20 percent), diarrhea (21 percent), constipation (24 percent), muscle cramps (24 percent), and infections (20 percent) have been reported but were usually not severe [<a href="#rid80">80</a>].</p><p></p><p class="headingAnchor" id="H3042695051"><span class="h2">Aggressive disease</span><span class="headingEndMark"> — </span>Treatment of patients who relapse or progress on therapy with major complications (eg, acute renal failure, extramedullary disease) is individualized. </p><p>Aggressive relapses may benefit from more aggressive treatment regimens that incorporate several new agents. As an example, a patient with aggressive progression on <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> may be treated with <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and dexamethasone (Dara-KPd). A clinical trial evaluating Dara-KPD is ongoing and will provide insight on the efficacy and safety of the combination (NCT04176718).    </p><p>The treatment of extramedullary relapse is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Extramedullary relapse'</a>.)</p><p class="headingAnchor" id="H1484128439"><span class="h2">Resource-poor settings</span><span class="headingEndMark"> — </span>Access to preferred three-drug regimens is limited in certain areas of the world by age restrictions or resource limitations. Patients in such settings can still benefit from the use of treatment regimens that are based on alkylating agents (eg, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> or <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>) and/or first generation immunomodulatory agents (eg, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>). Details regarding the use of these regimens and guidance regarding the choice of regimen are provided separately. (See  <a class="medical medical_review" href="/z/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H1175911187"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a>.)</p><p class="headingAnchor" id="H2159181503"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15531.html" rel="external">"Patient education: Multiple myeloma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/688.html" rel="external">"Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/690.html" rel="external">"Patient education: Multiple myeloma treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2950967932"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – There are many approved treatment combinations for patients with relapsed and/or refractory multiple myeloma (MM). Most patients experience serial relapses over time and will ultimately receive most if not all available agents at some point during their disease course. A preferred order for their use has not been established. Accompanying tables provide active drugs by class  (<a class="graphic graphic_table graphicRef121137" href="/z/d/graphic/121137.html" rel="external">table 5</a>) and major toxicities of selected treatment regimens  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 2</a>). General principles for treatment are provided separately. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Relapsed or refractory disease'</a>.)</p><p></p><p class="bulletIndent1">We typically suggest a three-drug regimen that includes a monoclonal antibody rather than one that does not (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). An exception would be for patients refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, in whom a monoclonal antibody is unlikely to be effective. Although direct comparisons between these combinations have not been conducted, network meta-analyses that incorporated both direct and indirect comparisons identified monoclonal antibody-containing three-drug combinations among the most active regimens in relapsed MM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess drug sensitivity</strong> – The choice of therapy for relapsed MM is influenced significantly by prior therapies received, response to those therapies, and likelihood of the disease being refractory to specific agents. In general, refractory disease is defined as progressing on or within 60 days of receiving standard doses of a specific therapy. It's important to consider that patients progressing on a low dose of an agent being administered in the context of maintenance therapy may still be sensitive to the same agent given at standard doses. (See <a class="local">'Assess drug sensitivity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenalidomide</strong><strong> sensitive </strong>–<strong> </strong>For most patients with lenalidomide-sensitive MM in first or second relapse, we suggest a lenalidomide-containing three-drug regimen rather than regimens that do not contain <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This includes patients who experience a biochemical relapse off lenalidomide, or while on low doses of single-agent lenalidomide (eg, 10 mg daily) administered as maintenance. This approach maximizes the benefit of lenalidomide-based treatment regimens and is supported by numerous phase 3 trials that have found it to be effective and well tolerated.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">Daratumumab</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DRd)  (<a class="graphic graphic_table graphicRef119710" href="/z/d/graphic/119710.html" rel="external">table 1</a>) is one such option. Other options include <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, lenalidomide, and dexamethasone (KRd); <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">ixazomib</a>, lenalidomide, and dexamethasone (IRd)  (<a class="graphic graphic_table graphicRef106536" href="/z/d/graphic/106536.html" rel="external">table 3</a>); and <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">elotuzumab</a>, lenalidomide, and dexamethasone (ERd). (See <a class="local">'Daratumumab, bortezomib, dexamethasone (DVd)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenalidomide</strong><strong> refractory</strong> – Treatment of lenalidomide-refractory disease is individualized based on response to prior therapy and expected toxicities  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory to </strong><strong>lenalidomide</strong><strong> alone</strong> – For patients with MM refractory to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> alone, we offer <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DVd); daratumumab, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and dexamethasone (DPd); <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">isatuximab</a>, pomalidomide, and dexamethasone (IsaPd); or bortezomib, pomalidomide, and dexamethasone (VPd). (See <a class="local">'Daratumumab, bortezomib, dexamethasone (DVd)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory to </strong><strong>lenalidomide</strong><strong> and </strong><strong>bortezomib</strong> – For patients with MM refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, we offer either <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (DKd) or <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">isatuximab</a>, carfilzomib, and dexamethasone (IsaKd). Other options in this context are DPd, IsaPd, and <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">elotuzumab</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and dexamethasone (EPd). (See <a class="local">'Daratumumab, carfilzomib, dexamethasone (DKd)'</a> above and <a class="local">'Isatuximab, carfilzomib, dexamethasone (IsaKd)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory to </strong><strong>lenalidomide</strong><strong> and </strong><strong>daratumumab</strong> – For patients with MM refractory to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, we offer the combination <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (KPd); VPd; <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and dexamethasone (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 4</a>); or <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">selinexor</a>, bortezomib, and dexamethasone (SVd). (See <a class="local">'Carfilzomib, pomalidomide, dexamethasone (KPd)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration considerations</strong> – All of these medications have associated risks and complex administration schedules, which are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies"</a>.) </p><p></p><p class="headingAnchor" id="H3795923160"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges extensive contributions of Robert A Kyle, MD to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Botta C, Ciliberto D, Rossi M, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv 2017; 1:455.</a></li><li><a class="nounderline abstract_t">van Beurden-Tan CHY, Franken MG, Blommestein HM, et al. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. J Clin Oncol 2017; 35:1312.</a></li><li><a class="nounderline abstract_t">Minakata D, Fujiwara SI, Yokoyama D, et al. Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol 2023; 200:694.</a></li><li><a class="nounderline abstract_t">Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood 2019; 134:668.</a></li><li><a class="nounderline abstract_t">Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 2020; 7:e370.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:1319.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 2018; 103:2088.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Oriol A, Nahi H, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 2023; 41:1590.</a></li><li><a class="nounderline abstract_t">Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372:142.</a></li><li><a class="nounderline abstract_t">Stewart AK, Dimopoulos MA, Masszi T, et al. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol 2016.</a></li><li><a class="nounderline abstract_t">Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2018; 36:728.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol 2017; 177:404.</a></li><li><a class="nounderline abstract_t">Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 374:1621.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood 2017; 130:2610.</a></li><li><a class="nounderline abstract_t">Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol 2018.</a></li><li><a class="nounderline abstract_t">Richardson PG, Kumar SK, Masszi T, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol 2021; 39:2430.</a></li><li><a class="nounderline abstract_t">Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. Blood 2021.</a></li><li><a class="nounderline abstract_t">Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 2015; 373:621.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 2017; 178:896.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer 2018; 124:4032.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Richardson PG, Bahlis NJ, et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9:e403.</a></li><li class="breakAll">Elotuzumab. United States prescribing information. Revised November 2015. US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf?et_cid=37060330&amp;et_rid=931330620&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f761035s000lbl.pdf (Accessed on November 30, 2015).</li><li><a class="nounderline abstract_t">Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:754.</a></li><li><a class="nounderline abstract_t">Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 2018; 103:2079.</a></li><li><a class="nounderline abstract_t">Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 2020; 20:509.</a></li><li><a class="nounderline abstract_t">Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 2023; 41:1600.</a></li><li><a class="nounderline abstract_t">Lu J, Fu W, Li W, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clin Lymphoma Myeloma Leuk 2021; 21:e699.</a></li><li><a class="nounderline abstract_t">Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20:781.</a></li><li><a class="nounderline abstract_t">Weisel K, Dimopoulos M, Moreau P, et al. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leuk Lymphoma 2020; 61:1850.</a></li><li><a class="nounderline abstract_t">Dimopoulos M, Weisel K, Moreau P, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 2021; 35:1722.</a></li><li><a class="nounderline abstract_t">Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020; 396:186.</a></li><li><a class="nounderline abstract_t">Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 2022; 23:65.</a></li><li><a class="nounderline abstract_t">Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2019; 134:421.</a></li><li><a class="nounderline abstract_t">Leleu X, Beksac M, Chou T, et al. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma 2021; 62:358.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761113s003lbl.pdf (Accessed on April 01, 2021).</li><li><a class="nounderline abstract_t">Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021; 397:2361.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22:801.</a></li><li><a class="nounderline abstract_t">Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017; 130:974.</a></li><li><a class="nounderline abstract_t">Siegel DS, Schiller GJ, Samaras C, et al. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia 2020; 34:3286.</a></li><li><a class="nounderline abstract_t">Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019; 394:2096.</a></li><li><a class="nounderline abstract_t">Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022; 23:416.</a></li><li><a class="nounderline abstract_t">Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol 2021; 194:120.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia 2021; 35:562.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2018; 379:1811.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol 2023; 41:568.</a></li><li><a class="nounderline abstract_t">Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J 2021; 11:89.</a></li><li><a class="nounderline abstract_t">Bringhen S, Mina R, Cafro AM, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia 2018; 32:1803.</a></li><li><a class="nounderline abstract_t">Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015; 126:2284.</a></li><li><a class="nounderline abstract_t">Sonneveld P, Zweegman S, Cavo M, et al. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. Hemasphere 2022; 6:e786.</a></li><li><a class="nounderline abstract_t">Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119:4375.</a></li><li><a class="nounderline abstract_t">Montefusco V, Corso A, Galli M, et al. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. Br J Haematol 2020; 188:907.</a></li><li><a class="nounderline abstract_t">Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 2016; 127:2569.</a></li><li><a class="nounderline abstract_t">Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007; 138:330.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212306s005lbl.pdf (Accessed on December 19, 2020).</li><li><a class="nounderline abstract_t">Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020; 396:1563.</a></li><li><a class="nounderline abstract_t">Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol 2021; 96:1120.</a></li><li><a class="nounderline abstract_t">Kumar SK, LaPlant BR, Reeder CB, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood 2016; 128:2415.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17:27.</a></li><li><a class="nounderline abstract_t">Chng WJ, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia 2017; 31:1368.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18:1327.</a></li><li><a class="nounderline abstract_t">Dimopoulos M, Siegel D, White DJ, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood 2019; 133:147.</a></li><li><a class="nounderline abstract_t">Orlowski RZ, Moreau P, Niesvizky R, et al. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk 2019; 19:522.</a></li><li><a class="nounderline abstract_t">Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91:929.</a></li><li><a class="nounderline abstract_t">Hrusovsky I, Emmerich B, von Rohr A, et al. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology 2010; 79:247.</a></li><li><a class="nounderline abstract_t">Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 2013; 160:649.</a></li><li><a class="nounderline abstract_t">Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777.</a></li><li><a class="nounderline abstract_t">Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol 2006; 55:897.</a></li><li><a class="nounderline abstract_t">Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27:5008.</a></li><li><a class="nounderline abstract_t">Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24:1934.</a></li><li><a class="nounderline abstract_t">Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118:2970.</a></li><li><a class="nounderline abstract_t">Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123:1826.</a></li><li><a class="nounderline abstract_t">Fouquet G, Pegourie B, Macro M, et al. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. Ann Oncol 2016; 27:902.</a></li><li><a class="nounderline abstract_t">Siegel DS, Schiller GJ, Song KW, et al. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. Br J Haematol 2020; 188:501.</a></li><li><a class="nounderline abstract_t">San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14:1055.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 2016; 128:497.</a></li><li><a class="nounderline abstract_t">Dimopoulos M, Weisel K, van de Donk NWCJ, et al. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. J Clin Oncol 2018; 36:2035.</a></li><li><a class="nounderline abstract_t">Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123.</a></li><li><a class="nounderline abstract_t">Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23:2147.</a></li><li><a class="nounderline abstract_t">Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164.</a></li></ol></div><div id="topicVersionRevision">Topic 121127 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296961" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28240968" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36661264" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31270103" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213342" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27705267" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30237262" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36599114" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25482145" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27601539" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341834" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28211560" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27119237" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054911" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29726031" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34111952" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33763699" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26035255" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28677826" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30204239" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35550060" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35550060" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27557302" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30237264" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32482541" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36413710" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34108127" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31097405" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32268815" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32895455" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682484" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871550" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31113777" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33112184" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33112184" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34097854" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34087126" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28637662" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32376855" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31735560" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35151415" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34036560" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32444867" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30403938" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35960908" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33980831" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479061" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26384354" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36204691" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422823" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31898319" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002117" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614819" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614819" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33189178" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34062004" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27702799" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671818" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025582" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28843768" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30478094" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31160237" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818280" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21372599" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293914" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16099887" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17052502" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720894" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20827286" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690557" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24421329" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26787238" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31588567" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24007748" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27226434" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29394124" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032762" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032763" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19626046" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19545290" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
